Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference

Audio By Carbonatix

AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2024--

Faeth Therapeutics, (Faeth) a clinical-stage biotechnology company, announced today that Anand Parikh, Chief Executive Officer (CEO), will participate in one-on-one investor meetings at the upcoming Jefferies Global Healthcare Conference being held June 4-6 in New York.

To schedule a meeting at the conference with Faeth’s CEO, please contact [email protected]. For more information about the conference, please contact your institutional sales representative at Jefferies.

Founded by renowned oncology researchers including Drs. Lew Cantley, Siddhartha Mukherjee, and Karen Vousden alongside CEO Anand Parikh, Faeth is focused on developing therapies targeting cancer metabolism. The role of metabolism in cancer proliferation is well established, yet remains a vastly under-exploited area, with very few cancer metabolism therapies in existence today. Faeth’s differentiated approach to targeting cancer metabolism leverages a systemic understanding of cancer metabolism, functional genomics, and computational biology to develop effective, less toxic therapies.

Faeth has a robust clinical and preclinical pipeline driven by the company’s MetabOS discovery platform, which leverages AI, machine learning, and curated data sets to identify targets matched to specific tumor genotypes.

Faeth's lead program, FTH-001/003, or "PIKTOR," includes serabelisib, a PI3Kɑ inhibitor, and sapanisertib, an mTORC 1/2 inhibitor, which together effectively shut down the PI3K pathway, the most commonly mutated pathway in cancer. PIKTOR, together with paclitaxel, has already shown outstanding results in a Phase 1b trial including endometrial, ovarian, and breast cancers. Faeth's second clinical program features FTH-002, a specially formulated amino acid sachet, which is administered in conjunction with an amino acid-restricted regimen and radio/chemotherapy.

About Faeth Therapeutics

Faeth Therapeutics is a clinical-stage biotechnology company at the forefront of oncology research with a robust clinical and preclinical pipeline powered by its AI-driven MetabOS discovery platform. Faeth’s lead program, PIKTOR, has shown outstanding clinical results in a Phase 1b trial and is advancing into a Phase 2 trial in endometrial cancer in 2024. For additional information, visit www.faeththerapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240530382789/en/

CONTACT: Patrick Schmidt

630-290-2787

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: TECHNOLOGY RESEARCH CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH SCIENCE ARTIFICIAL INTELLIGENCE ONCOLOGY

SOURCE: Faeth Therapeutics

Copyright Business Wire 2024.

PUB: 05/30/2024 09:00 AM/DISC: 05/30/2024 09:00 AM

http://www.businesswire.com/news/home/20240530382789/en